What is Genelux's operating income?

Genelux's total operating income in 2025 was -$33.21 million, based on the following breakdown: Total Gross Profit: $8 thousand Total Operating Expenses: $33.22 million

Genelux (GNLX) Financials

$2.87 +0.05 (+1.77%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$2.86 0.00 (-0.17%)

As of 07/17/2026 04:10 PM Eastern

Compare

Annual Income Statements for Genelux

This table shows Genelux's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-5.21	-28	-30	-32
Consolidated Net Income / (Loss)	-5.21	-28	-30	-32
Net Income / (Loss) Continuing Operations	-5.21	-28	-30	-32
Total Pre-Tax Income	-4.11	-28	-30	-32
Total Operating Income	-3.01	-24	-32	-33
Total Gross Profit	11	0.17	0.01	0.01
Total Revenue	11	0.17	0.01	0.01
Operating Revenue	11	0.17	0.01	0.01
Total Cost of Revenue	0.00	0.00	0.00	0.00
Total Operating Expenses	14	24	32	33
Selling, General & Admin Expense	5.00	12	13	13
Research & Development Expense	9.08	13	19	20
Total Other Income / (Expense), net	-1.09	-4.13	1.83	1.07
Interest & Investment Income	0.00	0.18	0.70	0.71
Other Income / (Expense), net	0.31	-3.15	1.13	0.36
Basic Earnings per Share	($0.57)	($1.16)	($0.95)	($0.86)
Weighted Average Basic Shares Outstanding	9.12M	24.43M	31.45M	37.18M
Diluted Earnings per Share	($0.57)	($1.16)	($0.95)	($0.86)
Weighted Average Diluted Shares Outstanding	9.12M	24.43M	31.45M	37.18M
Weighted Average Basic & Diluted Shares Outstanding	-	26.87M	34.60M	44.81M

This table shows Genelux's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-5.35	-6.77	-7.85	-6.58	-6.47	-8.98	-7.49	-7.46	-7.95	-9.25	-8.93
Consolidated Net Income / (Loss)	-5.35	-6.77	-7.85	-6.58	-6.47	-8.98	-7.49	-7.46	-7.95	-9.25	-8.93
Net Income / (Loss) Continuing Operations	-5.35	-6.66	-7.85	-6.58	-6.47	-8.98	-7.49	-7.46	-7.95	-9.25	-8.93
Total Pre-Tax Income	-5.35	-6.66	-7.85	-6.58	-6.47	-8.98	-7.49	-7.46	-7.95	-9.25	-8.93
Total Operating Income	-5.31	-7.00	-8.12	-6.89	-6.94	-9.75	-7.82	-7.79	-8.19	-9.41	-9.17
Total Gross Profit	0.00	-	0.01	0.00	0.00	-	0.00	0.00	0.00	0.01	0.00
Total Revenue	0.00	-	0.01	0.00	0.00	-	0.00	0.00	0.00	0.01	0.00
Operating Revenue	0.00	-	0.01	0.00	0.00	-	0.00	0.00	0.00	0.01	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	5.31	7.00	8.12	6.89	6.94	9.75	7.82	7.79	8.19	9.42	9.17
Selling, General & Admin Expense	2.49	2.84	4.11	2.48	2.89	3.23	3.12	3.03	3.45	3.77	3.39
Research & Development Expense	2.82	4.16	4.01	4.42	4.05	6.52	4.70	4.76	4.74	5.65	5.78
Total Other Income / (Expense), net	-0.04	0.23	0.27	0.32	0.47	0.77	0.32	0.34	0.24	0.17	0.24
Interest & Investment Income	0.00	0.18	0.11	0.16	0.22	-0.36	0.18	0.22	0.18	0.13	0.17
Other Income / (Expense), net	-0.04	-	0.15	0.15	0.25	1.13	0.14	0.11	0.07	0.04	0.07
Basic Earnings per Share	($0.20)	($0.20)	($0.29)	($0.22)	($0.19)	($0.25)	($0.21)	($0.20)	($0.21)	($0.24)	($0.20)
Weighted Average Basic Shares Outstanding	26.21M	24.43M	26.85M	29.69M	34.53M	31.45M	34.93M	37.95M	37.89M	37.18M	44.15M
Diluted Earnings per Share	($0.20)	($0.20)	($0.29)	($0.22)	($0.19)	($0.25)	($0.21)	($0.20)	($0.21)	($0.24)	($0.20)
Weighted Average Diluted Shares Outstanding	26.21M	24.43M	26.85M	29.69M	34.53M	31.45M	34.93M	37.95M	37.89M	37.18M	44.15M
Weighted Average Basic & Diluted Shares Outstanding	26.72M	26.87M	27.00M	34.54M	34.54M	34.60M	37.73M	37.77M	38.05M	44.81M	44.84M

This table details how cash moves in and out of Genelux's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-4.10	9.02	-0.85	-3.23
Net Cash From Operating Activities	-3.57	-20	-21	-25
Net Cash From Continuing Operating Activities	-3.57	-20	-21	-25
Net Income / (Loss) Continuing Operations	-5.21	-28	-30	-32
Consolidated Net Income / (Loss)	-5.21	-28	-30	-32
Depreciation Expense	0.55	0.50	0.24	0.24
Non-Cash Adjustments To Reconcile Net Income	2.52	10	7.66	7.91
Changes in Operating Assets and Liabilities, net	-1.69	-3.28	0.75	-1.05
Net Cash From Investing Activities	-0.05	-15	-8.13	12
Net Cash From Continuing Investing Activities	-0.05	-15	-8.13	12
Purchase of Property, Plant & Equipment	-0.05	-1.03	-0.38	-1.10
Purchase of Investments	0.00	-14	-29	-18
Sale and/or Maturity of Investments	-	0.00	21	32
Net Cash From Financing Activities	-0.48	44	29	9.90
Net Cash From Continuing Financing Activities	-0.48	44	29	9.90
Issuance of Common Equity	0.12	43	29	9.88
Other Financing Activities, net	-1.57	1.17	0.00	0.01

This table details how cash moves in and out of Genelux's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	2.73	-20	-5.36	3.80	-1.76	2.46	7.64	-9.66	-1.85	0.64	3.94
Net Cash From Operating Activities	-3.36	-6.91	-4.35	-6.82	-5.75	-4.30	-5.44	-7.06	-6.58	-6.20	-6.06
Net Cash From Continuing Operating Activities	-3.36	-6.91	-4.35	-6.82	-5.86	-4.30	-5.44	-7.06	-6.58	-5.97	-6.06
Net Income / (Loss) Continuing Operations	-5.35	-6.77	-7.85	-6.58	-6.47	-8.98	-7.49	-7.46	-7.95	-9.25	-8.93
Consolidated Net Income / (Loss)	-5.35	-6.77	-7.85	-6.58	-6.47	-8.98	-7.49	-7.46	-7.95	-9.25	-8.93
Depreciation Expense	0.13	0.10	0.08	0.04	0.06	0.06	0.06	0.06	0.06	0.06	0.01
Amortization Expense	-	-0.06	-0.15	-0.15	-0.25	-0.20	-0.14	-0.02	-0.03	-	-0.07
Non-Cash Adjustments To Reconcile Net Income	0.87	1.83	2.96	1.61	1.81	1.93	1.61	1.56	2.72	2.01	1.87
Changes in Operating Assets and Liabilities, net	0.99	-2.00	0.61	-1.74	-1.01	2.89	0.53	-1.21	-1.38	1.02	1.06
Net Cash From Investing Activities	-0.28	-14	-1.69	-17	3.99	6.67	3.51	-2.65	4.72	6.56	-8.54
Net Cash From Continuing Investing Activities	-0.28	-14	-1.69	-17	3.99	6.67	3.51	-2.65	4.72	6.56	-8.54
Purchase of Property, Plant & Equipment	-0.28	-0.24	-0.03	-0.23	-0.03	-0.10	-0.03	-0.12	-0.52	-0.44	-0.92
Purchase of Investments	-	-14	-3.16	-23	-1.98	-0.48	-2.46	-11	-5.26	-	-14
Sale and/or Maturity of Investments	-	-	1.50	6.50	6.00	7.25	6.00	8.00	11	7.00	6.78
Net Cash From Financing Activities	6.36	0.40	0.69	28	-	0.09	9.57	0.05	-	0.28	19
Net Cash From Continuing Financing Activities	6.36	0.40	0.69	28	-	0.09	9.57	0.05	-	0.28	19
Issuance of Common Equity	5.07	0.25	0.69	28	-	0.09	9.55	0.05	0.01	0.26	19
Other Financing Activities, net	1.32	0.15	0.00	-	-	-	0.01	-	-	-	0.01

This table presents Genelux's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	5.53	28	35	19
Total Current Assets	1.89	24	32	15
Cash & Equivalents	0.40	9.42	8.57	5.33
Short-Term Investments	0.00	14	22	9.26
Prepaid Expenses	1.50	1.01	0.65	0.54
Plant, Property, & Equipment, net	0.64	1.17	1.32	2.17
Total Noncurrent Assets	3.00	2.52	1.85	1.73
Other Noncurrent Operating Assets	3.00	2.52	1.85	1.73
Total Liabilities & Shareholders' Equity	5.53	28	35	19
Total Liabilities	41	8.42	8.44	7.48
Total Current Liabilities	32	6.55	6.90	6.23
Accounts Payable	6.78	3.78	5.57	4.36
Other Taxes Payable	2.85	2.12	-	1.44
Other Current Liabilities	0.44	0.65	0.33	0.43
Total Noncurrent Liabilities	9.69	1.87	1.54	1.26
Other Noncurrent Operating Liabilities	1.16	1.87	1.54	1.26
Commitments & Contingencies	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-36	19	26	12
Total Preferred & Common Equity	-36	19	26	12
Total Common Equity	-36	19	26	12
Common Stock	154	241	278	296
Retained Earnings	-190	-222	-251	-284
Treasury Stock	-0.43	-0.43	-0.43	-0.43
Accumulated Other Comprehensive Income / (Loss)	0.00	0.01	0.06	0.01

This table presents Genelux's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	34	25	45	40	39	32	25	32
Total Current Assets	31	21	35	36	36	29	22	27
Cash & Equivalents	30	4.06	7.86	6.10	16	6.55	-	9.27
Short-Term Investments	-	16	26	28	19	21	16	17
Prepaid Expenses	1.31	1.58	1.23	1.91	0.84	1.26	0.64	0.55
Plant, Property, & Equipment, net	1.02	1.12	1.31	1.28	1.29	1.34	1.79	3.08
Total Noncurrent Assets	1.87	2.36	9.00	3.03	1.75	1.67	1.64	2.54
Other Noncurrent Operating Assets	1.87	2.36	2.19	2.02	1.75	1.67	1.64	2.54
Total Liabilities & Shareholders' Equity	34	25	45	40	39	32	25	32
Total Liabilities	10	9.59	7.51	7.18	9.14	8.35	6.40	9.45
Total Current Liabilities	8.76	7.81	5.80	5.56	7.69	6.99	5.13	7.27
Accounts Payable	4.01	5.31	4.79	4.45	6.69	6.03	3.99	6.10
Other Taxes Payable	4.10	1.91	0.52	0.69	0.66	0.61	0.79	0.86
Other Current Liabilities	0.57	0.58	0.50	0.42	0.34	0.35	0.35	0.32
Total Noncurrent Liabilities	1.29	1.79	1.71	1.62	1.45	1.36	1.27	2.18
Other Noncurrent Operating Liabilities	1.29	1.79	1.71	1.62	1.45	1.36	1.27	2.18
Commitments & Contingencies	-	-	-	-	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	24	15	38	33	30	24	19	23
Total Preferred & Common Equity	24	15	38	33	30	24	19	23
Total Common Equity	24	15	38	33	30	24	19	23
Common Stock	239	245	274	276	289	291	293	316
Retained Earnings	-215	-229	-236	-242	-259	-266	-274	-292
Treasury Stock	-0.43	-0.43	-0.43	-0.43	-0.43	-0.43	-0.43	-0.43
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.01	-0.01	0.12	0.03	0.00	0.01	-0.01

This table displays calculated financial ratios and metrics derived from Genelux's official financial filings.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	26,717,676.00	-	38,051,771.00
DEI Adjusted Shares Outstanding	0.00	26,717,676.00	-	38,051,771.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-1.06	-	-0.84
Growth Metrics	-	-	-	-
Revenue Growth	0.00%	-98.46%	-95.29%	0.00%
EBITDA Growth	0.00%	-1,289.35%	-18.53%	-7.51%
EBIT Growth	0.00%	-912.12%	-11.90%	-7.48%
NOPAT Growth	0.00%	-702.02%	-31.16%	-4.79%
Net Income Growth	0.00%	-443.44%	-5.56%	-7.62%
EPS Growth	0.00%	-103.51%	18.10%	9.47%
Operating Cash Flow Growth	0.00%	-467.77%	-4.70%	-19.03%
Free Cash Flow Firm Growth	0.00%	0.00%	8.56%	-16.61%
Invested Capital Growth	0.00%	63.11%	-24.29%	33.98%
Revenue Q/Q Growth	0.00%	-28.57%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	-18.64%	-6.13%	0.59%
EBIT Q/Q Growth	0.00%	-16.69%	-5.60%	-0.61%
NOPAT Q/Q Growth	0.00%	-19.29%	-9.49%	1.00%
Net Income Q/Q Growth	0.00%	-13.07%	-7.99%	-0.85%
EPS Q/Q Growth	0.00%	0.00%	-5.56%	1.15%
Operating Cash Flow Q/Q Growth	0.00%	-36.23%	10.94%	-8.12%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	11.67%	-7.31%
Invested Capital Q/Q Growth	0.00%	35.91%	-134.69%	-31.28%
Profitability Metrics	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-17.06%	-15,430.00%	-388,637.50%	-407,650.00%
Operating Margin	-27.22%	-14,214.71%	-396,200.00%	-415,175.00%
EBIT Margin	-24.39%	-16,068.82%	-382,112.50%	-410,700.00%
Profit (Net Income) Margin	-47.05%	-16,645.29%	-373,362.50%	-401,812.50%
Tax Burden Percent	126.78%	100.39%	100.00%	100.00%
Interest Burden Percent	152.17%	103.18%	97.71%	97.84%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	14.55%	346.99%	-130.58%	-170.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-48.80%	-163.46%	-97.65%	-122.27%
Return on Assets (ROA)	-94.14%	-169.32%	-95.41%	-119.62%
Return on Common Equity (ROCE)	14.56%	347.46%	-130.58%	-170.00%
Return on Equity Simple (ROE_SIMPLE)	14.55%	-145.31%	-113.68%	0.00%
Net Operating Profit after Tax (NOPAT)	-2.11	-17	-22	-23
NOPAT Margin	-19.06%	-9,950.29%	-277,340.00%	-290,622.50%
Net Nonoperating Expense Percent (NNEP)	12.05%	905.81%	-28.41%	-39.11%
Return On Investment Capital (ROIC_SIMPLE)	-	-86.87%	-84.45%	-201.40%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	45.20%	6,804.71%	158,825.00%	167,137.50%
R&D to Revenue	82.02%	7,510.00%	237,475.00%	248,137.50%
Operating Expenses to Revenue	127.22%	14,314.71%	396,300.00%	415,275.00%
Earnings before Interest and Taxes (EBIT)	-2.70	-27	-31	-33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.89	-26	-31	-33
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	0.00	19.22	3.10	14.37
Price to Tangible Book Value (P/TBV)	0.00	19.22	3.10	14.37
Price to Revenue (P/Rev)	1.36	2,201.85	10,188.76	20,738.22
Price to Earnings (P/E)	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.57	2,065.43	6,326.89	18,913.84
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-
Debt to Equity	-0.70	0.00	0.00	0.00
Long-Term Debt to Equity	-0.24	0.00	0.00	0.00
Financial Leverage	-0.72	-0.15	-1.18	-1.20
Leverage Ratio	-0.15	-2.05	1.37	1.42
Compound Leverage Factor	-0.24	-2.11	1.34	1.39
Debt to Total Capital	-229.49%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	-151.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	-78.49%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	-0.20%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	329.70%	100.00%	100.00%	100.00%
Debt to EBITDA	-13.20	0.00	0.00	0.00
Net Debt to EBITDA	-12.99	0.00	0.00	0.00
Long-Term Debt to EBITDA	-4.51	0.00	0.00	0.00
Debt to NOPAT	-11.82	0.00	0.00	0.00
Net Debt to NOPAT	-11.63	0.00	0.00	0.00
Long-Term Debt to NOPAT	-4.04	0.00	0.00	0.00
Altman Z-Score	-53.88	13.09	-6.40	-12.70
Noncontrolling Interest Sharing Ratio	-0.06%	-0.13%	0.00%	0.00%
Liquidity Ratios	-	-	-	-
Current Ratio	0.06	3.69	4.57	2.43
Quick Ratio	0.01	3.54	4.48	2.34
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-23	-21	-25
Operating Cash Flow to CapEx	-7,287.76%	-1,978.05%	-5,571.65%	-2,301.28%
Free Cash Flow to Firm to Interest Expense	0.00	-22.15	0.00	0.00
Operating Cash Flow to Interest Expense	-2.54	-19.29	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-2.57	-20.27	0.00	0.00
Efficiency Ratios	-	-	-	-
Asset Turnover	2.00	0.01	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00
Fixed Asset Turnover	17.19	0.19	0.01	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-
Invested Capital	-10	-3.72	-4.62	-3.05
Invested Capital Turnover	-1.10	-0.02	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	6.36	-0.90	1.57
Enterprise Value (EV)	40	351	51	151
Market Capitalization	15	374	82	166
Book Value per Share	($3.93)	$0.73	$0.76	$0.30
Tangible Book Value per Share	($3.93)	$0.73	$0.76	$0.30
Total Capital	-11	19	26	12
Total Debt	25	0.00	0.00	0.00
Total Long-Term Debt	8.52	0.00	0.00	0.00
Net Debt	25	-23	-31	-15
Capital Expenditures (CapEx)	0.05	1.03	0.38	1.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-5.54	-6.25	-5.69
Debt-free Net Working Capital (DFNWC)	-13	18	25	8.91
Net Working Capital (NWC)	-30	18	25	8.91
Net Nonoperating Expense (NNE)	3.10	11	7.68	8.90
Net Nonoperating Obligations (NNO)	26	-23	-31	-15
Total Depreciation and Amortization (D&A)	0.81	1.09	-0.52	0.24
Debt-free, Cash-free Net Working Capital to Revenue	-124.07%	-3,260.00%	-78,125.00%	-71,125.00%
Debt-free Net Working Capital to Revenue	-120.48%	10,381.76%	308,062.50%	111,312.50%
Net Working Capital to Revenue	-268.65%	10,381.76%	308,062.50%	111,312.50%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($1.16)	($0.95)	($0.86)
Adjusted Weighted Average Basic Shares Outstanding	0.00	24.43M	31.45M	37.18M
Adjusted Diluted Earnings per Share	$0.00	($1.16)	($0.95)	($0.86)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	24.43M	31.45M	37.18M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	26.87M	34.60M	44.81M
Normalized Net Operating Profit after Tax (NOPAT)	-2.11	-17	-22	-23
Normalized NOPAT Margin	-19.06%	-9,950.29%	-277,340.00%	-290,622.50%
Pre Tax Income Margin	-37.11%	-16,580.00%	-373,362.50%	-401,812.50%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	-1.92	-25.99	0.00	0.00
NOPAT to Interest Expense	-1.50	-16.09	0.00	0.00
EBIT Less CapEx to Interest Expense	-1.95	-26.97	0.00	0.00
NOPAT Less CapEx to Interest Expense	-1.53	-17.07	0.00	0.00
Payout Ratios	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Genelux's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	26,182,892.00	26,717,676.00	26,865,473.00	26,996,740.00	34,535,471.00	-	34,604,296.00	37,734,967.00	37,773,443.00	38,051,771.00	44,805,811.00
DEI Adjusted Shares Outstanding	26,182,892.00	26,717,676.00	26,865,473.00	26,996,740.00	34,535,471.00	-	34,604,296.00	37,734,967.00	37,773,443.00	38,051,771.00	44,805,811.00
DEI Earnings Per Adjusted Shares Outstanding	-0.20	-0.25	-0.29	-0.24	-0.19	-	-0.22	-0.20	-0.21	-0.24	-0.20
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-100.00%	0.00%	-95.29%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-179.87%	-144.83%	8.60%	-30.30%	-32.00%	-25.79%	3.41%	-11.38%	-17.56%	-2.14%	-18.11%
EBIT Growth	-184.32%	-126.28%	16.80%	-24.91%	-25.05%	-23.14%	3.62%	-13.96%	-21.47%	-2.16%	-18.56%
NOPAT Growth	-171.68%	-126.28%	-25.58%	-27.75%	-30.79%	-39.24%	3.68%	-13.06%	-18.05%	3.45%	-17.34%
Net Income Growth	-208.88%	-93.62%	24.26%	-12.97%	-20.99%	-32.64%	4.56%	-13.38%	-22.93%	-3.02%	-19.17%
EPS Growth	-140.82%	0.00%	45.28%	4.35%	5.00%	-25.00%	27.59%	9.09%	-10.53%	4.00%	4.76%
Operating Cash Flow Growth	-35.91%	-355.20%	5.14%	-25.95%	-71.22%	37.74%	-24.83%	-3.44%	-14.39%	-44.10%	-11.48%
Free Cash Flow Firm Growth	0.00%	0.00%	-619.14%	-792.46%	-516.60%	47.43%	32.14%	38.85%	38.09%	-37.80%	-76.28%
Invested Capital Growth	0.00%	63.11%	22.66%	41.58%	66.06%	-24.29%	-15.69%	-46.55%	-18.03%	33.98%	37.44%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%
EBITDA Q/Q Growth	0.84%	-33.59%	-15.26%	14.66%	-0.45%	-22.81%	14.95%	1.59%	-6.03%	-15.09%	1.64%
EBIT Q/Q Growth	0.85%	-30.88%	-13.76%	15.38%	0.74%	-24.20%	16.36%	-0.05%	-5.79%	-15.38%	2.92%
NOPAT Q/Q Growth	1.63%	-31.92%	-15.91%	15.07%	-0.71%	-40.44%	19.82%	0.31%	-5.16%	-14.86%	2.56%
Net Income Q/Q Growth	8.18%	-26.60%	-16.00%	16.23%	1.66%	-38.80%	16.53%	0.48%	-6.63%	-16.31%	3.45%
EPS Q/Q Growth	13.04%	0.00%	-45.00%	24.14%	13.64%	-31.58%	16.00%	4.76%	-5.00%	-14.29%	16.67%
Operating Cash Flow Q/Q Growth	38.04%	-105.84%	36.99%	-56.73%	15.77%	25.16%	-26.34%	-29.88%	6.86%	5.72%	2.26%
Free Cash Flow Firm Q/Q Growth	112.33%	-639.84%	37.74%	2.97%	-27.74%	31.87%	19.63%	12.56%	-29.33%	-51.62%	-2.81%
Invested Capital Q/Q Growth	-21.90%	35.91%	-22.19%	38.81%	29.17%	-134.69%	-13.74%	22.49%	42.96%	-31.28%	-7.77%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%
EBITDA Margin	0.00%	0.00%	-100,387.50%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-116,437.50%	0.00%
Operating Margin	0.00%	0.00%	-101,437.50%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-117,650.00%	0.00%
EBIT Margin	0.00%	0.00%	-99,550.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-117,187.50%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	-98,125.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-115,587.50%	0.00%
Tax Burden Percent	100.00%	101.67%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	99.93%	95.07%	98.57%	97.58%	96.68%	104.12%	97.60%	97.08%	97.85%	98.63%	98.10%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-104.15%	346.99%	-290.10%	-88.57%	-96.85%	-130.58%	-131.36%	-98.73%	-123.35%	-170.00%	-127.28%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	-40.54%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-34.89%	0.00%
Return on Assets (ROA)	0.00%	0.00%	-39.96%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-34.41%	0.00%
Return on Common Equity (ROCE)	-104.15%	347.46%	-290.10%	-88.57%	-96.85%	-130.58%	-131.36%	-98.73%	-123.35%	-170.00%	-127.28%
Return on Equity Simple (ROE_SIMPLE)	-104.15%	0.00%	-170.93%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.71	-4.90	-5.68	-4.82	-4.86	-6.82	-5.47	-5.45	-5.74	-6.59	-6.42
NOPAT Margin	0.00%	0.00%	-71,006.25%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-82,355.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-10.93%	148.53%	-15.39%	-5.19%	-4.96%	-7.96%	-7.38%	-5.85%	-7.91%	-11.69%	-8.18%
Return On Investment Capital (ROIC_SIMPLE)	-	-25.17%	-37.66%	-12.81%	-14.68%	-25.97%	-18.33%	-22.82%	-30.85%	-57.07%	-28.01%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	51,412.50%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	47,075.00%	0.00%
R&D to Revenue	0.00%	0.00%	50,125.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	70,675.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	101,537.50%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	117,750.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-5.35	-7.00	-7.96	-6.74	-6.69	-8.62	-7.68	-7.68	-8.13	-9.38	-9.10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.22	-6.97	-8.03	-6.85	-6.89	-8.77	-7.76	-7.63	-8.09	-9.32	-9.16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	26.69	19.22	11.45	1.40	2.47	3.10	3.13	4.53	8.53	14.37	4.73
Price to Tangible Book Value (P/TBV)	26.69	19.22	11.45	1.40	2.47	3.10	3.13	4.53	8.53	14.37	4.73
Price to Revenue (P/Rev)	2,694.20	2,201.85	21,593.12	6,580.46	10,231.13	10,188.76	0.00	0.00	0.00	20,738.22	13,553.76
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2,568.87	2,065.43	19,139.75	1,524.33	5,848.63	6,326.89	0.00	0.00	0.00	18,913.84	10,277.63
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.24	-0.15	-1.59	-1.13	-1.14	-1.18	-1.22	-1.11	-1.08	-1.20	-1.16
Leverage Ratio	1.42	-2.05	2.21	1.28	1.30	1.37	1.42	1.26	1.26	1.42	1.35
Compound Leverage Factor	1.42	-1.95	2.18	1.25	1.26	1.42	1.38	1.22	1.24	1.40	1.33
Debt to Total Capital	0.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.83%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	2.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	29.76	15.49	-2.62	-2.83	-1.23	-4.31	-2.94	-3.74	-0.77	-8.62	-5.97
Noncontrolling Interest Sharing Ratio	0.00%	-0.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.56	3.69	2.72	6.01	6.47	4.57	4.67	4.18	4.20	2.43	3.68
Quick Ratio	3.41	3.54	2.51	5.80	6.13	4.48	4.57	4.00	3.16	2.34	3.60
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	2.09	-11	-7.01	-6.80	-8.69	-5.92	-4.76	-4.16	-5.38	-8.16	-8.39
Operating Cash Flow to CapEx	-1,211.91%	-2,843.62%	-14,513.33%	-2,992.98%	-21,288.89%	-4,481.25%	-18,116.67%	-6,138.26%	-1,271.76%	-1,421.79%	-657.87%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.23	0.19	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-5.80	-3.72	-4.54	-2.78	-1.97	-4.62	-5.26	-4.07	-2.32	-3.05	-3.29
Invested Capital Turnover	-0.08	-0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-5.80	6.36	1.33	1.98	3.83	-0.90	-0.71	-1.29	-0.36	1.57	1.97
Enterprise Value (EV)	611	351	153	12	47	51	58	80	138	151	82
Market Capitalization	641	374	173	53	82	82	93	108	159	166	108
Book Value per Share	$0.92	$0.73	$0.56	$1.40	$0.96	$0.76	$0.86	$0.63	$0.49	$0.30	$0.51
Tangible Book Value per Share	$0.92	$0.73	$0.56	$1.40	$0.96	$0.76	$0.86	$0.63	$0.49	$0.30	$0.51
Total Capital	24	19	15	38	33	26	30	24	19	12	23
Total Debt	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-30	-23	-20	-40	-35	-31	-35	-28	-21	-15	-26
Capital Expenditures (CapEx)	0.28	0.24	0.03	0.23	0.03	0.10	0.03	0.12	0.52	0.44	0.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.41	-5.54	-6.23	-4.57	-3.65	-6.25	-6.85	-5.73	-4.49	-5.69	-6.73
Debt-free Net Working Capital (DFNWC)	22	18	13	29	30	25	28	22	16	8.91	19
Net Working Capital (NWC)	22	18	13	29	30	25	28	22	16	8.91	19
Net Nonoperating Expense (NNE)	1.63	1.87	2.17	1.75	1.61	2.15	2.02	2.00	2.21	2.66	2.51
Net Nonoperating Obligations (NNO)	-30	-23	-20	-40	-35	-31	-35	-28	-21	-15	-26
Total Depreciation and Amortization (D&A)	0.13	0.03	-0.07	-0.12	-0.20	-0.14	-0.08	0.05	0.03	0.06	-0.06
Debt-free, Cash-free Net Working Capital to Revenue	-3,111.34%	-3,260.00%	-77,850.00%	-57,112.50%	-45,562.50%	-78,125.00%	0.00%	0.00%	0.00%	-71,125.00%	-84,087.50%
Debt-free Net Working Capital to Revenue	9,438.66%	10,381.76%	167,487.50%	363,337.50%	380,150.00%	308,062.50%	0.00%	0.00%	0.00%	111,312.50%	243,525.00%
Net Working Capital to Revenue	9,421.85%	10,381.76%	167,487.50%	363,337.50%	380,150.00%	308,062.50%	0.00%	0.00%	0.00%	111,312.50%	243,525.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.20)	($0.20)	($0.29)	($0.22)	($0.19)	($0.25)	($0.21)	($0.20)	($0.21)	($0.24)	($0.20)
Adjusted Weighted Average Basic Shares Outstanding	26.21M	24.43M	26.85M	29.69M	34.53M	31.45M	34.93M	37.95M	37.89M	37.18M	44.15M
Adjusted Diluted Earnings per Share	($0.20)	($0.20)	($0.29)	($0.22)	($0.19)	($0.25)	($0.21)	($0.20)	($0.21)	($0.24)	($0.20)
Adjusted Weighted Average Diluted Shares Outstanding	26.21M	24.43M	26.85M	29.69M	34.53M	31.45M	34.93M	37.95M	37.89M	37.18M	44.15M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	26.72M	26.87M	27.00M	34.54M	34.54M	34.60M	37.73M	37.77M	38.05M	44.81M	44.84M
Normalized Net Operating Profit after Tax (NOPAT)	-3.71	-4.90	-5.68	-4.82	-4.86	-6.82	-5.47	-5.45	-5.74	-6.59	-6.42
Normalized NOPAT Margin	0.00%	0.00%	-71,006.25%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-82,355.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	-98,125.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-115,587.50%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Genelux’s latest quarter shows a company still heavily reliant on its cash reserve and balance-sheet strength, but with ongoing operating losses and no meaningful product revenue yet. For Q1 2026, the company reported $0 in revenue and a net loss of $8.9 million, versus a net loss of $9.2 million in Q4 2025. The business continues to spend aggressively on research and development while funding operations largely through its existing cash and investment portfolio, plus equity issuance.

Cash and investments remain substantial: Genelux ended Q1 2026 with about $26.2 million in cash and short-term investments, which provides some near-term operating runway.
Operating loss improved slightly sequentially: Q1 2026 operating loss was $9.2 million, a modest improvement from $9.4 million in Q4 2025.
Other income helped offset losses: Interest and other income contributed $243,000 in Q1 2026, which slightly cushioned the bottom line.
Equity financing boosted liquidity: The company raised $18.5 million from common equity issuance in Q1 2026, reinforcing its cash position.
Balance sheet remains equity-heavy: Total equity was $22.9 million versus $9.5 million in liabilities, so the company is not currently overleveraged.
Debt appears minimal: The latest balance sheet does not show meaningful debt, reducing financial pressure from interest expense.
Share count is rising: Weighted average basic shares were 44.2 million in Q1 2026, up from 37.2 million in Q4 2025, pointing to dilution risk.
No revenue generation yet: Genelux reported zero revenue in every quarter shown, so losses are not being offset by commercial sales.
Persistent quarterly losses: The company has posted quarterly net losses ranging from about $6.5 million to $9.2 million over the past year, showing the business is still far from profitability.
Cash burn remains significant: Q1 2026 operating cash flow was negative $6.1 million, and investing outflows brought total cash use to a negative position before financing.

Longer-term trend: Compared with early 2024, Genelux has become more dependent on financing. Its cash and investments have fluctuated, but the bigger story is that operating losses have remained consistently high while common stock issuance has repeatedly filled the funding gap. The quarter-to-quarter trend suggests the company is maintaining liquidity for research and development, but investors should expect ongoing dilution unless revenue eventually materializes.

Bottom line: Genelux still has a workable cash cushion and no obvious debt burden, but the stock remains highly speculative because the company has no sales, recurring losses, and ongoing dilution. The key thing retail investors should watch is whether clinical or commercial progress can eventually translate into revenue before cash burn forces another financing round.

07/18/26 02:15 PM ETAI Generated. May Contain Errors.

Genelux Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Genelux's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Genelux's net income appears to be on an upward trend, with a most recent value of -$32.15 million in 2025, rising from -$5.21 million in 2022. The previous period was -$29.87 million in 2024. See Genelux's forecast for analyst expectations on what's next for the company.

Genelux's total operating income in 2025 was -$33.21 million, based on the following breakdown:

Total Gross Profit: $8 thousand
Total Operating Expenses: $33.22 million

Over the last 3 years, Genelux's total revenue changed from $11.07 million in 2022 to $8 thousand in 2025, a change of -99.9%.

Genelux's total liabilities were at $7.48 million at the end of 2025, a 11.4% decrease from 2024, and a 81.9% decrease since 2022.

In the past 3 years, Genelux's cash and equivalents has ranged from $397 thousand in 2022 to $9.42 million in 2023, and is currently $5.33 million as of their latest financial filing in 2025.

Over the last 3 years, Genelux's book value per share changed from -3.93 in 2022 to 0.30 in 2025, a change of -107.7%.

Related Companies

Financial statements for NASDAQ:GNLX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genelux (GNLX) Financials

Financials Breakdown Chart

Key Financial Trends

Genelux Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genelux (GNLX) Financials

Annual Income Statements for Genelux

Quarterly Income Statements for Genelux

Annual Cash Flow Statements for Genelux

Quarterly Cash Flow Statements for Genelux

Annual Balance Sheets for Genelux

Quarterly Balance Sheets for Genelux

Annual Metrics And Ratios for Genelux

Quarterly Metrics And Ratios for Genelux

Financials Breakdown Chart

Key Financial Trends

Genelux Financials - Frequently Asked Questions

When does Genelux's fiscal year end?

How has Genelux's net income changed over the last 3 years?

What is Genelux's operating income?

How has Genelux's revenue changed over the last 3 years?

How much debt does Genelux have?

How much cash does Genelux have?

How has Genelux's book value per share changed over the last 3 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools